Exenatide
Brand: Byetta (BID) / Bydureon (weekly ER)
Antidiabetic
GLP-1 receptor agonist
Pharmacokinetics
| Half-life | 2.4 hours |
| Tmax | 2.1 h |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | PK shown for immediate-release (BID). Extended-release weekly has different absorption profile; avoid in severe renal impairment. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Nausea, vomiting, diarrhea, headache; injection-site reactions (ER)
Contraindications:
Severe renal impairment/ESRD (avoid)
Precautions:
Pancreatitis risk; slows gastric emptying; caution with gastroparesis; hypoglycemia with insulin/sulfonylureas